Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;100(12):e487-90.
doi: 10.3324/haematol.2015.127985. Epub 2015 Aug 20.

Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia

Manja Meggendorfer  1 , Andreia de Albuquerque  1 , Niroshan Nadarajah  1 , Tamara Alpermann  1 , Wolfgang Kern  1 , Kimberly Steuer  1 , Karolína Perglerová  2 , Claudia Haferlach  1 , Susanne Schnittger  1 , Torsten Haferlach  3
Affiliations

Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia

Manja Meggendorfer et al. Haematologica. 2015 Dec.
No abstract available

Keywords: MDS; mutation analysis; s-AML.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cytogenetic characterization of paired MDS and s-AML samples. (A) Illustration of the cytogenetic patterns with the support of CYDAS (http://www.cydas.org/OnlineAnalysis/). Chromosomal gains are marked in green to the right, losses in red to the left. The thickness of the bars represents the number of cases showing the respective chromosomal gain or loss. Illustrations of the cytogenetic alterations in the MDS state (left panel) and in the s-AML state (right panel) are shown. (B) Table giving the case numbers of recurrent cytogenetic abnormalities in both disease states. None of the differences was statistically significant. P-values are given.
Figure 2.
Figure 2.
Molecular characterization of paired MDS and s-AML samples. (A) Illustration of all 38 samples in both disease states, MDS and s-AML. Each column represents one patient. White: no mutation/normal karyotype; gray: mutation/aberrant karyotype; red: aberration acquired at s-AML state; green: aberration only during MDS. The upper lane shows data from MDS and the lower lane shows data from s-AML for each of the genes analyzed. (B) Associations of aberrations with MDS or s-AML are depicted by the odds ratio of MDS/s-AML, the 95% confidence intervals are given as width of the bars. An odds ratio <1 indicates that mutations are less frequent in MDS and more common in the s-AML state. Red bars indicate differences between MDS and s-AML states. Numbers of cases with respective mutations and karyotype aberrations as well as P-values are given in the table beside.
Figure 3.
Figure 3.
Associations of aberrations to MDS progressing to s-AML and to the MDS control cohort (not including patients with s-AML transformation) are depicted by the odds ratios of MDS/MDS without s-AML transformation; the 95% confidence intervals are given. Odds ratios >1 indicate that mutations are more frequent in MDS progressing to AML and less frequent in the MDS control cohort. Red bars indicate statistically significant differences between MDS progressing to s-AML and the MDS control cohort. Numbers of cases with respective mutations and karyotype aberrations as well as P-values are given in the table beside.
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: International Agency for Research on Cancer (IARC), 2008.
    1. Jabbour E, Takahashi K, Wang X, et al. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013;88(10):831–837. - PMC - PubMed
    1. de Souza Fernandez T, Ornellas MH, Otero de Carvalho L, Tabak D, Abdelhay E. Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia. Leuk Res. 2000;24(10):839–848. - PubMed
    1. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood. 2006;107(10):3847–3853. - PubMed
    1. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100(1):59–66. - PubMed